Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
-
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
-
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
-
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
-
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
-
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
-
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
-
Opus Genetics to Participate in Leading Medical Conferences in May 2026
-
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting